500 adults to help unravel mysteries of rare liver disease

NCT ID NCT06512454

Recruiting now Knowledge-focused Sponsor: Takeda Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This study follows 500 adults with alpha-1 antitrypsin deficiency (AATD) for up to 5 years to see how their liver disease progresses without any special treatment. Researchers will track changes in liver scarring, symptoms, and overall health using medical records and yearly questionnaires. The goal is to better predict who might get worse or better, and to improve how doctors monitor this condition in everyday care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALPHA1-ANTITRYPSIN DEFICIENCY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

alpha 1-antitrypsin deficiency

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALPHA1-ANTITRYPSIN DEFICIENCY

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Beaumont Hospital
RECRUITING

Dublin, Dublin 9, Ireland
Hospital Universitari Vall d'Hebron
RECRUITING

Barcelona, Spain
Queen Elizabeth Hospital Birmingham
RECRUITING

Birmingham, B15 2GW, United Kingdom
University of Florida
RECRUITING

Gainesville, Florida, 32608, United States
University of South Carolina
RECRUITING

Charleston, South Carolina, 29425, United States
Universitätsklinikum Aachen
RECRUITING

Aachen, 52074, Germany
Vanderbilt University Medical Center
RECRUITING

Nashville, Tennessee, 37212, United States
Vienna General Hospital (AKH Wien)
RECRUITING

Vienna, 1090, Austria

More trials for these conditions

Other studies related to the condition(s) this trial covers.